In this issue of Blood, Cortes et al demonstrate that the optimal benefit-to-risk outcome for ponatinib-treated patients with chronic myeloid leukemia (CML) who had failed prior therapy was a starting dose of 45 mg, which was reduced to 15 mg upon attainment of a response.
CML Highlights of the 63rd ASH Annual Meeting
Join our two experts to hear about key aspects of the scientific program such as the Live Q&A Session on CML: 'Success breeds more success', the ASH-FDA Joint Symposium on newly approved drugs: 'Treatment landscape in the era of novel therapies' and oral and poster abstracts on basic and translational research in CML, mechanisms of resistance and expanded therapies and progress with response predictors and TKI discontinuation.
iCMLF Knowledge Centre an interactive online resource providing educational content on CML patient management, options for molecular monitoring and practical considerations of BCR-ABL1 testing
What is D*action?
D*action started out as a 5 year (now on-going) public health project to provide education and research to SOLVE the vitamin D deficiency epidemic, by measuring vitamin D serum levels, collecting health data from participants, and tracking the health effects of getting to levels of 40-60 ng/ml (100-150 nmol/L).
Published by GrassrootsHealth Nutrient Research Institute
Conclusions: In this first controlled study comparing treatments for resistant/intolerant (R/I) pts with CML, asciminib, a first-in-class STAMP inhibitor, demonstrated statistically significant and clinically meaningful superiority in efficacy compared with BOS (primary objective), deeper MR rates, and a favorable safety profile. These results support the use of asciminib as a new treatment option in CML, particularly in R/I pts who received ≥2 prior TKIs.
Chronic myeloid leukemia (CML) is a blood cancer. Unlike other cancers CML treatment is lifelong and many patients experience side effects. For those patients who respond well to treatment and achieve deep molecular remission, quality of life is impacted because of continuous treatment. In this review, we look at emerging clinical trials which aim to investigate which patients can safely stop treatment.
Conclusions: These updated results continue to support 50 mg of dasatinib daily as an effective and safe dose for newly diagnosed early CML-CP.
MyeloidScan – Long COVID in patients with myeloid blood cancers
Have you had COVID 19 infection? We need to find out more about long covid affects people like you – can you help us?
We would like to share with you an opportunity to take part in a study to investigate the impact of COVID-19 infection in people with myeloid blood cancers.
What is the study for?
Asciminib, a first-in-class STAMP inhibitor, may be a new treatment option for patients with chronic myeloid leukaemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors.
A British Society for Haematology Guideline on the diagnosis and management of CML
Authors:
Graeme Smith, Jane Apperley, Dragana Milojkovic, Nicholas C. P. Cross, Letizia Foroni, Jenny Byrne, Andy Goringe, Anupama Rao, Jamshid Khorashad, Hugues de Lavallade, Adam J. Mead, Wendy Osborne, Chris Plummer, Gail Jones, Mhairi Copland, behalf of British Society for Haematology